WO2026139085 - CASEIN KINASE 1α (CK1α) MOLECULAR GLUE DEGRADER
National phase entry is expected:
Publication Number
WO/2026/139085
Publication Date
02.07.2026
International Application No.
PCT/CN2025/146824
International Filing Date
29.12.2025
Title **
[English]
CASEIN KINASE 1α (CK1α) MOLECULAR GLUE DEGRADER
[French]
AGENT DE DÉGRADATION DE COLLE MOLÉCULAIRE DE CASÉINE KINASE 1α (CK1α)
[Chinese]
酪蛋白激酶1α(CK1α)分子胶降解剂
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
CHEN, Wenmin
XU, Fuming
MA, Yichao
LIU, Xiaobing
BU, Licong
SHEN, Jie
Priority Data
202411944222.9
27.12.2024
CN
202510122741.5
26.01.2025
CN
202510393847.9
31.03.2025
CN
202510642159.1
19.05.2025
CN
202510921455.5
04.07.2025
CN
202511261796.0
05.09.2025
CN
202511389826.6
26.09.2025
CN
202511826354.6
05.12.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3574 | |
| EPO | Filing, Examination, Granting | 20325 | |
| Japan | Filing, Examination, Granting | 2448 | |
| South Korea | Filing, Examination, Granting | 2873 | |
| USA | Filing, Examination, Granting | 6640 |
Total:
35,860
Contact Us
Abstract[English]
The present disclosure relates to a compound or a pharmaceutically acceptable salt thereof useful as a casein kinase 1α modulator, and a method for preventing or treating cancer by administering an effective amount of the compound or the pharmaceutically acceptable salt thereof to a subject in need thereof to degrade the casein kinase 1α.[French]
La présente divulgation concerne un composé ou un sel pharmaceutiquement acceptable de celui-ci utile en tant que modulateur de caséine kinase 1α, et une méthode de prévention ou de traitement du cancer par administration d'une quantité efficace du composé ou du sel pharmaceutiquement acceptable de celui-ci à un sujet en ayant besoin pour dégrader la caséine kinase 1α.[Chinese]
本公开涉及一种可用作酪蛋白激酶1α调节剂的化合物或其可药用的盐，以及通过向有需要的受试者施用有效量的所述化合物或其可药用的盐来降解酪蛋白激酶1α，进而预防或治疗癌症的方法。